Patient With Kidney Disease Articles & Analysis
43 news found
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...
EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...
Here is a brief excerpt: “A recently developed injector with a very novel method to map these vessels is to use carbon dioxide as a contrast agent which is safe in these patients especially in Body procedures. This technique has been endorsed by various medical and surgical societies like the European society of vascular surgery which promotes it in appropriate groups of ...
“The ongoing study of posoleucel in kidney transplant patients has demonstrated a favorable, preliminary safety and tolerability profile and encouraging cell persistence to date. ...
ByKalaris
“These results demonstrated that patients on long-term voclosporin therapy continue to experience clinically relevant benefits, including significant preservation of kidney function long-term, with no unexpected, new safety ...
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention ...
“Aurinia continues to expand its clinical evidence supporting LUPKYNIS as a reliable treatment option for people and HCPs working to protect their patients’ kidneys from the devastating impact of lupus nephritis,” said Neil Solomons, M.D., Chief Medical Officer at Aurinia. ...
Based on the initial Phase 2 prevention study data, AlloVir initiated a global Phase 3 registrational study of posoleucel for the prevention of clinically significant infections and end-organ disease from posoleucel’s six target viruses in high-risk allo-HCT patients, either as prophylactic therapy in patients without viremia or preemptive ...
ByKalaris
(Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus ...
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
He is among a handful of surgeons who perform complex robotic surgeries such as robotic Inferior Vena Cava (IVC) tumor thrombectomy, robotic cystectomy with intracorporeal urinary diversions, robotic transplant nephrectomy and robotic nephrectomies for Polycystic Kidney Disease. Dr. Gupta treats patients with urological cancers such as bladder, ...
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and nephrologists) about ...
The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. ...
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance. Preliminary results show that Orviglance was well tolerated in patients with liver impairment. The study is part of the ...
Unfortunately, contrast dye can be toxic to the kidneys, especially in patients with preexisting kidney disease — and Sheldon has significant kidney dysfunction. ...
If approved, Kapruvia® will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients. ...
A July 2019 White House executive order on kidney care (the Advancing American Kidney Health Initiative) proposed that 80% of new patients with end-stage renal disease (ESRD) be treated with either kidney transplantation or home dialysis by 2025, a significant increase from current rates, which are below 20%. ...
Xeltis initiated a European first-in-human trial on aXess in patients with kidney failure or advanced kidney disease requiring dialysis. A number of patients have already been successfully implanted as part of the trial to ...
In addition, the Marketing Authorization Application for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients is undergoing review with the European Medicines Agency. ...